丹参饮片中丹参酮Ⅱ_A含量的考察和分析

目的考察当前市场上丹参饮片中丹参酮ⅡA的含量并对结果做出分析。方法按照《山东省中药炮制规范》测定丹参酮ⅡA的含量,对测定结果与标准规定进行比较并分析原因。结果丹参饮片中丹参酮ⅡA的含量普遍偏低,其原因是由多因素所致的。结论本文考察分析了丹参饮片中丹参酮ⅡA的含量,可为丹参饮片标准的提高提供依据。     

丹参酮对女性迟发性痤疮患者血清性激素水平的影响及疗效观察

目的探讨丹参酮对女性迟发性痤疮患者血清性激素水平的影响及临床疗效。方法选择门诊女性迟发性痤疮患者115例,随机分为：治疗组（A组）60例,口服丹参酮胶囊4粒,4次/d;对照组（B组）55例,口服多西环素片0.1 g,2次/d,4周后减为0.1 g,1次/d。8周为一疗程,疗程结束后进行疗效评价。并对治疗组（A组）患者,于治疗前后分别采用电化学发光免疫分析法检测其卵泡期血清六项性激素水平,另选40例相应年龄段的健康女性作健康对照组（C组）。结果A组痊愈率为36.7%,有效率为78.4%;B组痊愈率为14.5%,有效率为45.4%,A组痊愈率及有效率均高于B组,差异有统计学意义（P〈0.05或〈0.01）。A组女性迟发性痤疮患者治疗前血清睾酮水平较C组明显升高（P〈0.05）,而治疗后血清睾酮水平与C组相比差异无统计学意义（P〉0.05）。结论女性迟发性痤疮发病的主要原因与雄激素分泌增多有关。丹参酮具有抗雄激素作用,对女性迟发性痤疮的疗效确切,且无耐药性及明显不良反应。     

丹参酮ⅡA磺酸钠对高脂性脂肪肝大鼠肝脏脂质过氧化的影响

目的研究丹参酮ⅡA磺酸钠对高脂性脂肪肝（HFL）大鼠肝脏脂质过氧化的影响,并初步探讨其作用机制。方法用高脂饲料诱发大鼠HFL模型,8周后将建模成功的大鼠随机分为模型组、丹参酮ⅡA磺酸钠（大、小剂量组）和阳性药易善复（PPC）组,每组均给予高脂饲料及相应药物,正常对照组喂以基础饲料。连续给药6周后比较各组间肝指数、血脂、血清丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（ASL）活性和超氧化物歧化酶（SOD）、丙二醛（MDA）的含量;检测肝脂质、肝脏组织中SOD、MDA含量并进行肝脏病理学检查。结果丹参酮ⅡA磺酸钠可显著降低HFL模型大鼠肝指数,降低血清和肝组织中TG、TC、MDA水平,降低血清LDL-C含量和ALT、AST活性;增加血清和肝组织中SOD活性及HDL-C含量,与模型组相比差异显著（P〈0.05或〈0.01）;并可明显减少肝细胞浆内脂滴分布的程度和炎症范围。结论丹参酮ⅡA磺酸钠可通过改善肝功能及脂质代谢紊乱,减少肝中脂质沉积,减轻肝组织损伤,对高脂性脂肪肝有一定的治疗作用。     

Effects of tanshinone II A on the myocardial hypertrophy signal transduction system protein kinase B in rats

Objective： To study the effect of tanshinone ⅡA on the cell signal transduction system protein kinase B （Akt） in rats with hypertrophy of the myocardium induced by partial constriction of the thoracic aorta. Methods： Rat models of myocardial hypertrophy were established by the thoracic aorta partial constriction method. Forty-eight rats were randomly divided into the sham-operative group, the model group, the valsartan treatment group, and the low-, medium-, and high-dose tanshinone treatment groups. The heart mass index （HMI）, left ventricular mass index （LVMI）, ejection fraction （EF）, left ventricular posterior wall （LVPW）, and interventricular septal thickness （IVS） were detected by high-frequency ultrasonography. The myocardial fiber diameter （MFD） was detected by HE staining, and the contents of p-Akt and p-Gsk3β in the myocardium were detected by Western blot. Results： Compared with the sham-operative group, the levels of HMI, LVMI, LVPW, IVS, and MFD were increased respectively in the other groups （P〈0.05）; the contents of p-Akt and p-Gsk3β were also increased in the other groups. Compared with the model group, the levels of HMI, LVMI, LVPW, IVS, and MFD were decreased respectively in all treatment groups （P〈0.05）; the contents of p-Akt and p-Gsk3β were decreased in all treatment groups as well. There was no significant difference, however, among the low-, medium-, and high-dose tanshinone treatment groups and the valsartan treatment group （P〉0.05）. Conclusion： Tanshinone HE A can prevent myocardial hypertrophy by its action on the protein kinase B （Akt） signaling pathway.     

Novel polymeric nanoparticles containing tanshinone IIA for the treatment of hepatoma

Novel polylactic acid nanoparticles containing tanshinone IIA (TS-PLA-NPs) were synthesized by a single oil-in-water emulsion/solvent evaporation method. In this study, the optimized nanoparticles were characterized for morphology, mean particle size, zeta potential, entrapment efficiency, drug-loading content, X-ray diffractometer measurement, and in vitro release. The obtained nanoparticles were spherical and intact. The mean particle size was 192.5 nm with polydispersity index being 0.029 and zeta potential ? 26.27 mV. The mean entrapment efficiency and loading of tanshinone IIA (TSIIA) in TS-PLA-NPs were 86.35 and 1.61%, respectively. The in vitro release study was performed at pH 7.4 using a dialysis membrane. Without initial burst effect, the TSIIA sustained release from TS-PLA-NPs for more than 7 days. The mean in vitro cumulative release percentage of TSIIA from TS-PLA-NPs vs. time curve fitted well with the Higuchi Equation (Q = 2.0365 + 13.564 × t_1/2, r = 0.9950). In pharmacokinetics and tissue distribution studies, the concentrations of TSIIA are higher in hepatoma and lower in blood, heart, kidney, spleen, and lung at 2 h after TS-PLA-NPs was administered via caudal vein. TS-PLA-NPs were effective in destroying the human liver cancer cells by the Mono-nuclear cell direct cytotoxicity assay (MTT) assay, and the growth-inhibitory effect of TS-PLA-NPs on human liver cancer cells was concentration and time dependent. The effect of TS-PLA-NPs on hepatoma in mice was also performed. The results of TS-PLA-NPs were markedly more effective than both of TSIIA and blank PLA nanoparticles in preventing tumor growth and increasing survival time of mice with hepatoma. This study provided support for the new paradigm, the application of TSIIA for the treatment of hepatoma.     

Tanshinone IIA ameliorates chronic arthritis in mice by modulating neutrophil activities

Rheumatoid arthritis (RA) is a chronic immune inflammatory disease mediated by the influx of immune cells into the synovial joint space. As Tanshinone IIA (TIIA) has potent anti‐oxidant and anti‐inflammatory activities, we used the adjuvant‐induced arthritis (AA) murine model of RA to investigate the impact of TIIA on RA and immune cell activation. The anti‐arthritic activity of TIIA was investigated in an adjuvant‐induced arthritis model of RA in mice. Myeloperoxidase and neutrophil elastase expression levels were assessed in ankle joints by immunohistochemistry analysis. Immune cell infiltration was evaluated in air pouch experiments. Proinflammatory cytokines expression levels were determined by quantitative real‐time polymerase chain reaction (PCR) and enzyme‐linked immunosorbent assays. Neutrophil extracellular traps (NETs) were assessed by immunostaining and confocal microscopy. Treatment with TIIA alleviated cartilage erosion and neutrophil infiltration in the ankle joints of AA mice and reduced proinflammatory cytokine expression levels in sera. TIIA suppressed interleukin‐6 and tumour necrosis factor‐α expression and release in neutrophils and promoted neutrophil apoptosis. TIIA also inhibited the NET formation of neutrophils. Our findings demonstrated that TIIA can ameliorate RA effectively by targeting neutrophils, indicating that TIIA may act as a potential therapeutic for RA.     

Tanshinone I inhibits tumor angiogenesis by reducing STAT3 phosphorylation at TYR705 and hypoxia-induced HIF-1α accumulation in both endothelial and tumor cells

Tanshinone I (Tanshinone-1), a major active principle of Salvia miltiorrhiza (Danshen), has been shown to overcome tumor drug resistance and metastasis. Here we report that tanshinone-1 inhibits angiogenesis. Tanshinone-1 inhibited proliferation, migration and tube formation of vascular endothelial cells, rat aortic ring sprouting and the neovascularization of the chick chorioallantoic membrane in a concentration-dependent manner. In endothelial cells, tanshinone-1 almost completely inhibited phosphorylation of Stat3 at Tyr705 regardless of hypoxia or normoxia but only slightly decreased the hypoxia-induced HIF-1α accumulation. In tumor cells, contrastively, tanshinone-1 could not only make phosphorylation of Stat3 at Tyr705 disappear but also reduce the hypoxia-induced accumulation of HIF-1α to its baseline levels at normoxia. Consequently, VEGF secretion from tumor cells was reduced, which could potentiate the direct inhibition of tanshinone-1 on endothelial cells. Together with its overcoming tumor drug resistance and metastasis, our results reveal unique characteristics of tanshinone-1 and its improved derivatives as promising angiogenesis inhibitors.     

丹参酮ⅡA磺酸钠联合糖皮质激素用于小儿紫癜性肾炎的疗效观察

目的：研究探讨丹参酮ⅡA磺酸钠联合糖皮质激素用于小儿紫癜性肾炎的疗效。方法：选择过敏性紫癜患儿82例,随机分为观察组与对照组,对照组患儿采用口服小剂量泼尼松进行治疗,观察组患儿采用丹参酮ⅡA磺酸钠联合糖皮质激素进行治疗,对比分析两组患儿的治疗结果和不良反应情况。结果：治疗后观察组患儿的尿红细胞计数为（18.5±7.9）,24 h尿蛋白定量为（782±364）,均低于对照组,差异有统计学意义（P〈0.05）。结论：采用丹参酮ⅡA磺酸钠联合糖皮质激素对紫癜性肾炎患儿进行治疗,治疗效果好,安全性高,值得进行推广应用。     

丹参酮Ⅱ_A磺酸钠联合参麦注射液治疗慢性肺心病84例

目的观察丹参酮ⅡA磺酸钠联合参麦注射液在慢性肺源性心脏病中的治疗效果。方法 168例慢性肺源性心脏病患者,随机分为治疗组和对照组各84例。治疗组在常规治疗基础上,给予丹参酮ⅡA磺酸钠40~80mg,参麦注射液50~100mL,稀释后静脉滴注,每日1次,连用1周;对照组给予常规治疗,观察治疗后的临床效果及血液流变学和血气分析的变化情况;1周后继续使用巩固至出院。结果治疗组84例患者中显效48例(57.14%)、有效29例(34.52%)、无效7例(8.33%),总有效率91.67%,平均住院天数(10.4±2.8)d;对照组84例患者中显效26例(30.95%)、有效44例(52.38%)、无效14例(16.67%),总有效率83.33%,平均住院天数(13.2±3.6)d。2组比较,P0.05;治疗组各证型疗效比较,气虚血瘀证总有效率96.15%最高,与其他各证型比较,P0.05;治疗后患者血液流变学指标和血气分析指标治疗组明显改善(P0.05)。结论丹参酮ⅡA磺酸钠联合参麦注射液中西医结合治疗慢性肺心病疗效显著,对气虚血瘀型患者疗效明显。